PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32472067-5	2020	Hyperthermia also occurs in WT mice that received intracerebroventricular injection of TRPV1 antagonist AMG9810 upon exposure to 35.0  C. Heat loss behaviors, sleeping and body licking, were deficient in TRPV1 KO mice exposed to warm temperatures.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	104-111	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	87-92	
32472067-5	2020	Hyperthermia also occurs in WT mice that received intracerebroventricular injection of TRPV1 antagonist AMG9810 upon exposure to 35.0  C. Heat loss behaviors, sleeping and body licking, were deficient in TRPV1 KO mice exposed to warm temperatures.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	104-111	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	204-209	
30507785-5	2019	Knockout of TRPV1 or pretreatment with the TRPV1 antagonists, AMG9810 or 5"-iodoresiniferatoxin (5"-IRTX), significantly reduced C5a-induced mechanical sensitization.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	62-69	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	12-17	
34691215-5	2021	Osthole-induced calcium influx was inhibited by AMG9810, an antagonist of TRPV1.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	48-55	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	74-79	
31676602-10	2019	Ongoing pain from inflamed masseter muscle was also reduced in KI mice, and was further inhibited by the TRPV1 antagonist AMG9810.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	122-129	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	105-110	
33361699-7	2021	Blockade of the transient receptor potential vanilloid 1 (TRPV1), an element of the tonic retrograde endocannabinoid machinery by AMG9810 (10 microM) or antagonizing cannabinoid receptor type-1 (CB1) by AM251 (1 microM) abolished the effect.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	130-137	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	16-56	
33361699-7	2021	Blockade of the transient receptor potential vanilloid 1 (TRPV1), an element of the tonic retrograde endocannabinoid machinery by AMG9810 (10 microM) or antagonizing cannabinoid receptor type-1 (CB1) by AM251 (1 microM) abolished the effect.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	130-137	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	58-63	
33239060-9	2020	TRPV1 inhibition using the antagonist AMG9810-induced MM cell apoptosis and synergized with bortezomib, overcoming both CXCR4-dependent stroma-mediated and acquired resistance.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	38-45	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	0-5	
30507785-5	2019	Knockout of TRPV1 or pretreatment with the TRPV1 antagonists, AMG9810 or 5"-iodoresiniferatoxin (5"-IRTX), significantly reduced C5a-induced mechanical sensitization.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	62-69	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	43-48	
26819760-5	2016	Immepip-induced scratching behavior could be blocked by TRPV1 antagonist AMG9810 and PLC pathway inhibitor U73122.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	73-80	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	56-61	
30007240-9	2018	The anticonvulsant activity of acetaminophen was antagonized by capsazepine and AMG9810, two transient receptor potential vanilloid-1 (TRPV1) antagonists.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	80-87	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	93-133	
30007240-9	2018	The anticonvulsant activity of acetaminophen was antagonized by capsazepine and AMG9810, two transient receptor potential vanilloid-1 (TRPV1) antagonists.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	80-87	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	135-140	
24641282-7	2014	The enhancement was dependent upon Ca2+ influx and was abolished in the presence of EGTA, the Ca2+ channel inhibitor SKF96365, the transient receptor potential (TRP) channel blocker ruthenium red, and the TRPV1 antagonists capsazepine and AMG9810.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	239-246	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	205-210	
21349818-0	2011	TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.	3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide	17-24	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	0-5